Sugi Predict

Sugi Predict / Compounds / SCHEMBL666895

SCHEMBL666895

SCHEMBL666895

[CH2]C(O)CN1CCCCC1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.64
▸ KMT2A Q03164 2/20 0.64
▸ ATM Q13315 2/20 0.52
▸ MAPT P10636 2/20 0.52
▸ HSD17B10 Q99714 2/20 0.47
▸ ANPEP P15144 1/20 0.43
▸ ERAP2 Q6P179 1/20 0.43
▸ CYP2D6 P10635 2/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ POLB P06746 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HIF1A Q16665 1/20 0.39
▸ MAOB P27338 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ KDM4E B2RXH2 3/20 0.38
▸ ACE2 Q9BYF1 1/20 0.38
▸ LMNA P02545 1/20 0.37
▸ ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL666115 1.00 MEN1 (0.64) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL665319 1.00 MEN1 (0.64) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL4373095 0.97 — —
SCHEMBL4388841 0.97 — —
SCHEMBL1504812 0.97 — —
SCHEMBL1829243 0.92 — —
SCHEMBL7156858 0.78 MEN1 (0.70) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL11118757 0.78 MEN1 (1.00) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL13024066 0.78 MEN1 (0.70) MEN1KMT2AATMMAPTHSD17B10
SCHEMBL665275 0.75 USP2 (0.67) MEN1KMT2AATMHSD17B10ANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106458821-A BH4 antagonists and methods related thereto 爱默蕾大学 2017-02-22 — — CN claimed
CN-101616920-A The 1-H-pyrazolo (3,4b) pyrimidine derivatives and as the purposes of mitotic kinase conditioning agent BIOGEN IDEC INC 2009-12-30 — — CN claimed
CN-1642949-A Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterial, related compositions and methods ORTHO MCNEIL PHARM INC (US) 2005-07-20 — — CN claimed
EP-1470123-A1 BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIALS, RELATED COMPOSITIONS AND METHODS Ortho-Mcneil Pharmaceutical, Inc. (US) 2004-10-27 — — EP claimed
US-20040067994-A1 BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIALS, AND RELATED COMPOSITIONS AND METHODS PAGET STEVEN D (US) 2004-04-08 — — US claimed
US-6608081-B2 Treating pneumonia ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-08-19 — — US claimed
WO-2003064415-A1 BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIAL, RELATED COMPOSITIONS AND METHODS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2003-08-07 — — WO claimed
US-20020161029-A1 Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-10-31 — — US claimed
EP-0328000-B1 Indolocarbazole derivatives, process for their preparation and medicines containing same GOEDECKE AG (DE) 1995-01-18 — — EP claimed
WO-1993024490-A1 USE OF INDOLOCARBAZOLS IN AIDS TREATMENT Gödecke Aktiengesellschaft (DE) 1993-12-09 — — WO claimed
EP-0328000-A2 Indolocarbazole derivatives, process for their preparation and medicines containing same GÖDECKE AKTIENGESELLSCHAFT (DE) 1989-08-16 — — EP claimed
US-4554274-A ANTIARRHYTHMIA AND ADRENERGIC BLOCKING AGENTS KALI-CHEMIE PHARMA GMBH (DE) 1985-11-19 — — US claimed
US-4552877-A ANTIARRHYTHMIA AGENTS KALI-CHEMIE PHARMA GMBH (DE) 1985-11-12 — — US claimed
EP-0029115-B1 N(B)-QUATERNARY 10-BROMO-AJMALINE AND 10-BROMO-ISOAJMALINE DERIVATIVES, PROCESS AND INTERMEDIATES FOR PREPARING THE DERIVATIVES AND MEDICAMENTS CONTAINING THE DERIVATIVES Kali-Chemie Pharma GmbH (DE) 1984-09-12 — — EP claimed
EP-0029116-B1 N(B)-QUATERNARY 10-BROMO-SANDWICINE AND 10-BROMO-ISOSANDWICINE DERIVATIVES, PROCESS AND INTERMEDIATES FOR PREPARING THE DERIVATIVES AND MEDICAMENTS CONTAINING THESE DERIVATIVES Kali-Chemie Pharma GmbH (DE) 1984-09-05 — — EP claimed
JP-58067667-A — — None — — JP disclosed
CN-106458821-A BH4 antagonists and methods related thereto 爱默蕾大学 2017-02-22 — — CN disclosed
US-4554274-A ANTIARRHYTHMIA AND ADRENERGIC BLOCKING AGENTS KALI-CHEMIE PHARMA GMBH (DE) 1985-11-19 — — US disclosed
US-4552877-A ANTIARRHYTHMIA AGENTS KALI-CHEMIE PHARMA GMBH (DE) 1985-11-12 — — US disclosed
JP-S5867667-A 1-SUBSTITUTED-4-PHENYL-ISONICOPETINIC ACID ESTER KAYAKU:KK 1983-04-22 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161029-A1 Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods OXA1L, NDUFS3, CYCS MEN1 4298/4885KMT2A 3290/4885ATM 2666/4885
US-20040067994-A1 BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIALS, AND RELATED COMPOSITIONS AND METHODS OXA1L, NDUFS3, CYCS MEN1 4298/4885KMT2A 3290/4885ATM 2666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.